Researchers reveal unique characteristics of previously unexplored protein FAM110A

FHS
July 16, 2024
4:42 pm

An international research collaboration, led by Prof. Dr. Robert Grosse (Centre for Integrative Biological Signalling Studies and Institute of Clinical and Experimental Pharmacology and Toxicology, University of Freiburg), Dr. Libor Macurek (Institute of Molecular Genetics, Czech Academy of Sciences, Prague) and Dr. Zdenek Lansky (Institute of Biotechnology, Czech Academy of Sciences, Prague) has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.

US FDA grants breakthrough therapy status for Nuvalent’s NVL-655

NVL-655 is intended to treat locally advanced or metastatic ALK-positive NSCLC patients previously treated with two or more ALK TKIs. Credit: Sebastian Kaulitzki / Shutterstock.com.

May 17, 2024

Braxia Announces Annual General and Special Meeting | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – September 10, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”) announced today

September 12, 2024

Bloodletting therapy offers promising treatment for heat stroke

Heat stroke is primarily classified into exertional and non-exertional forms. Exertional heat stroke results from strenuous physical activity in high heat, while non-exertional heat stroke

November 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.